Corrigendum to “Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study” [Eur J Cancer 213 (December) (2024) 115078]
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
January 2026
|
| In: |
European journal of cancer
Year: 2026, Jahrgang: 232, Pages: 1-2 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2025.116106 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ejca.2025.116106 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S095980492500992X 
|
| Verfasserangaben: | Arun A. Azad, Karim Fizazi, Nobuaki Matsubara, Fred Saad, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Robert J. Jones, Stefanie Zschäbitz, Jan Oldenburg, Neal D. Shore, Curtis Dunshee, Joan Carles, Andre P. Fay, Xun Lin, Liza DeAnnuntis, Nicola Di Santo, Michael A. Zielinski, Neeraj Agarwal |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1950646637 | ||
| 003 | DE-627 | ||
| 005 | 20260130085357.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260130s2026 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2025.116106 |2 doi | |
| 035 | |a (DE-627)1950646637 | ||
| 035 | |a (DE-599)KXP1950646637 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Azad, Arun |e VerfasserIn |0 (DE-588)1388439468 |0 (DE-627)1950646327 |4 aut | |
| 245 | 1 | 0 | |a Corrigendum to “Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study” [Eur J Cancer 213 (December) (2024) 115078] |c Arun A. Azad, Karim Fizazi, Nobuaki Matsubara, Fred Saad, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Robert J. Jones, Stefanie Zschäbitz, Jan Oldenburg, Neal D. Shore, Curtis Dunshee, Joan Carles, Andre P. Fay, Xun Lin, Liza DeAnnuntis, Nicola Di Santo, Michael A. Zielinski, Neeraj Agarwal |
| 246 | 3 | 0 | |a two |
| 264 | 1 | |c January 2026 | |
| 300 | |b Illustrationen | ||
| 300 | |a 2 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 13. November 2025, Artikelversion: 18. November 2025 | ||
| 500 | |a Gesehen am 30.01.2026 | ||
| 700 | 1 | |a Fizazi, Karim |e VerfasserIn |4 aut | |
| 700 | 1 | |a Matsubara, Nobuaki |e VerfasserIn |4 aut | |
| 700 | 1 | |a Saad, Fred |e VerfasserIn |4 aut | |
| 700 | 1 | |a De Giorgi, Ugo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Joung, Jae Young |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fong, Peter C. C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jones, Robert J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zschäbitz, Stefanie |d 1983- |e VerfasserIn |0 (DE-588)1037698827 |0 (DE-627)75589894X |0 (DE-576)391727206 |4 aut | |
| 700 | 1 | |a Oldenburg, Jan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Shore, Neal D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dunshee, Curtis |e VerfasserIn |4 aut | |
| 700 | 1 | |a Carles, Joan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fay, Andre P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lin, Xun |e VerfasserIn |4 aut | |
| 700 | 1 | |a DeAnnuntis, Liza |e VerfasserIn |4 aut | |
| 700 | 1 | |a Di Santo, Nicola |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zielinski, Michael A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Agarwal, Neeraj |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 232(2026) vom: Jan., Artikel-ID 116106, Seite 1-2 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Corrigendum to “Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study” [Eur J Cancer 213 (December) (2024) 115078] |
| 773 | 1 | 8 | |g volume:232 |g year:2026 |g month:01 |g elocationid:116106 |g pages:1-2 |g extent:2 |a Corrigendum to “Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study” [Eur J Cancer 213 (December) (2024) 115078] |
| 787 | 0 | 8 | |i Ergänzung zu |a Azad, Arun |t Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer |d 2024 |w (DE-627)1950645398 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2025.116106 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S095980492500992X |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20260130 | ||
| 993 | |a Article | ||
| 994 | |a 2026 | ||
| 998 | |g 1037698827 |a Zschäbitz, Stefanie |m 1037698827:Zschäbitz, Stefanie |d 910000 |d 910100 |d 50000 |e 910000PZ1037698827 |e 910100PZ1037698827 |e 50000PZ1037698827 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 9 | ||
| 999 | |a KXP-PPN1950646637 |e 4865586229 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"family":"Azad","display":"Azad, Arun","role":"aut","given":"Arun"},{"display":"Fizazi, Karim","family":"Fizazi","given":"Karim","role":"aut"},{"display":"Matsubara, Nobuaki","family":"Matsubara","role":"aut","given":"Nobuaki"},{"given":"Fred","role":"aut","display":"Saad, Fred","family":"Saad"},{"display":"De Giorgi, Ugo","family":"De Giorgi","role":"aut","given":"Ugo"},{"role":"aut","given":"Jae Young","display":"Joung, Jae Young","family":"Joung"},{"display":"Fong, Peter C. C.","family":"Fong","given":"Peter C. C.","role":"aut"},{"display":"Jones, Robert J.","family":"Jones","given":"Robert J.","role":"aut"},{"role":"aut","given":"Stefanie","display":"Zschäbitz, Stefanie","family":"Zschäbitz"},{"family":"Oldenburg","display":"Oldenburg, Jan","role":"aut","given":"Jan"},{"display":"Shore, Neal D.","family":"Shore","given":"Neal D.","role":"aut"},{"family":"Dunshee","display":"Dunshee, Curtis","role":"aut","given":"Curtis"},{"family":"Carles","display":"Carles, Joan","given":"Joan","role":"aut"},{"given":"Andre P.","role":"aut","display":"Fay, Andre P.","family":"Fay"},{"display":"Lin, Xun","family":"Lin","given":"Xun","role":"aut"},{"family":"DeAnnuntis","display":"DeAnnuntis, Liza","given":"Liza","role":"aut"},{"display":"Di Santo, Nicola","family":"Di Santo","given":"Nicola","role":"aut"},{"role":"aut","given":"Michael A.","family":"Zielinski","display":"Zielinski, Michael A."},{"family":"Agarwal","display":"Agarwal, Neeraj","given":"Neeraj","role":"aut"}],"id":{"doi":["10.1016/j.ejca.2025.116106"],"eki":["1950646637"]},"recId":"1950646637","relHost":[{"corporate":[{"display":"European Organization for Research on Treatment of Cancer","role":"isb"},{"role":"isb","display":"European Association for Cancer Research"},{"display":"European School of Oncology","role":"isb"}],"language":["eng"],"titleAlt":[{"title":"EJC online"}],"part":{"volume":"232","text":"232(2026) vom: Jan., Artikel-ID 116106, Seite 1-2","extent":"2","pages":"1-2","year":"2026"},"title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"origin":[{"publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","dateIssuedDisp":"1992-","dateIssuedKey":"1992","publisher":"Elsevier ; Pergamon Press"}],"pubHistory":["28.1992 -"],"disp":"Corrigendum to “Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study” [Eur J Cancer 213 (December) (2024) 115078]European journal of cancer","type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"266883400","id":{"zdb":["1468190-0"],"issn":["1879-0852"],"eki":["266883400"]}}],"physDesc":[{"noteIll":"Illustrationen","extent":"2 S."}],"name":{"displayForm":["Arun A. Azad, Karim Fizazi, Nobuaki Matsubara, Fred Saad, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Robert J. Jones, Stefanie Zschäbitz, Jan Oldenburg, Neal D. Shore, Curtis Dunshee, Joan Carles, Andre P. Fay, Xun Lin, Liza DeAnnuntis, Nicola Di Santo, Michael A. Zielinski, Neeraj Agarwal"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title_sort":"Corrigendum to “Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study” [Eur J Cancer 213 (December) (2024) 115078]","title":"Corrigendum to “Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study” [Eur J Cancer 213 (December) (2024) 115078]"}],"origin":[{"dateIssuedKey":"2026","dateIssuedDisp":"January 2026"}],"note":["Online verfügbar: 13. November 2025, Artikelversion: 18. November 2025","Gesehen am 30.01.2026"]} | ||
| SRT | |a AZADARUNFICORRIGENDU2026 | ||